Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024GlobeNewsWire • Monday
Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate HighlightsGlobeNewsWire • 03/18/24
Avenue Therapeutics to Present BAER-101 Preclinical Data at American Society for Experimental Neurotherapeutics (ASENT) 2024 Annual MeetingGlobeNewsWire • 03/11/24
Avenue Therapeutics Announces Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101 in a Translational Model of Absence EpilepsyGlobeNewsWire • 02/22/24
Avenue Therapeutics to Present at Sidoti January Micro-Cap Investor ConferenceGlobeNewsWire • 01/11/24
Avenue Therapeutics Enters into Warrant Exercise Transactions for $5.0 Million in ProceedsGlobeNewsWire • 01/05/24
Avenue Therapeutics Reaches Final Agreement with the U.S. FDA for the Phase 3 Safety Study for IV TramadolGlobeNewsWire • 01/04/24
Avenue Therapeutics Announces Completion of Enrollment in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)GlobeNewsWire • 01/02/24
Avenue Therapeutics to Present at American Epilepsy Society 2023 Annual MeetingGlobeNewsWire • 12/01/23
Avenue Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate HighlightsGlobeNewsWire • 11/13/23
Avenue Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment ConferenceGlobeNewsWire • 09/05/23
Avenue Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate HighlightsGlobeNewsWire • 08/10/23
Avenue Therapeutics Announces High Potency and Full Efficacy in a Model of Generalized Seizures for its Novel GABA-A Receptor Potentiator, BAER-101, Supporting Phase 2 Clinical StudyGlobeNewsWire • 08/01/23
Avenue Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)GlobeNewsWire • 07/27/23
Avenue Therapeutics Announces Agreement with the FDA on the Study Design and Analysis Approach of the Phase 3 Safety Study for IV TramadolGlobeNewsWire • 07/25/23
Avenue Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate HighlightsGlobeNewsWire • 05/12/23
Avenue Therapeutics Announces Regulatory Update Based on Type C Meeting with FDA and Next Steps in the Development of IV TramadolGlobeNewsWire • 04/17/23
Avenue Therapeutics Reports Full Year 2022 Financial Results and Recent Corporate HighlightsGlobeNewsWire • 03/30/23
Avenue Therapeutics Provides Regulatory Update on IV Tramadol and Other Corporate UpdatesGlobeNewsWire • 03/08/23
Avenue Therapeutics Enters into a Transformational License Agreement with AnnJi Pharmaceutical to Develop and Commercialize AJ201, a First-in-Class Clinical Asset for the Treatment of Spinal and Bulbar Muscular AtrophyGlobeNewsWire • 03/02/23